Wall Street's Insights Into Key Metrics Ahead of BioMarin (BMRN) Q2 Earnings

Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.57 per share in its forthcoming report, representing an increase of 5.6% year over year. Revenues are projected to reach $660.51 million, increasing 11% from the same quarter last year. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a ...